促性腺素释放素拮抗剂在体外受精-胚胎移植中的LH峰抑制

目的:探讨促性腺素释放素拮抗剂(GnRHA)在体外受精-胚胎移植(IVF-ET)中应用的效果。方法:回顾性分析使用GnRHA方案的306个IVF-ET周期(实验组)和使用常规促性腺素释放素激动剂(GnRHa)长方案266个IVF-ET周期(对照组)。结果:实验组Gn用量少于对照组,但无显著性差异;GnRHA用药时间明显少于GnRHa;实验组平均获卵数、中、重度OHSS发生率明显低于对照组;优质胚胎移植率明显高于对照组。而二组受精率、卵裂率、优质胚胎移植率、胚胎冷冻率、种植率、妊娠率均无统计学差异。二组均无LH峰提早出现。结论:GnRHA为我们提供了一种安全的控制性超排卵方案,并可有效抑制LH峰过早出现。     

在低卵巢储备患者中灵活的促性腺激素拮抗剂方案优于标准拮抗剂方案

目的:评估灵活、低剂量促性腺激素释放激素拮抗剂(Gn RH-A)方案和标准的Gn RH-A方案在卵巢储备功能减退患者体外受精-胚胎移植(IVF-ET)/卵胞质单精子注射(ICSI)的超促排卵过程中的应用价值。方法:回顾性分析108例卵巢储备功能减退患者IVF-ET周期,其中58例使用灵活而低剂量Gn RH-A方案(A组),50例使用标准Gn RH-A方案(B组)。比较各组实验室指标和临床结局。结果:A组Gn RH-A使用天数、剂量均少于B组(P0.05);A组h CG注射日E2峰值、优质胚胎数、新鲜胚胎移植周期临床妊娠率、累积临床妊娠率均高于B组(P0.05);但促排卵天数、Gn用量、内膜厚度、获卵数、成熟卵数、受精率、新鲜胚胎移植周期移植胚胎数、冻融胚胎移植周期临床妊娠率、累积着床率组间无统计学差异(P0.05)。结论:与标准Gn RH-A方案相比,灵活而低剂量的Gn RH-A使用方案可获得更多的优质胚胎并降低Gn RH-A的使用总剂量和天数,提高累积临床妊娠率和胚胎着床率。     

来曲唑联合促性腺激素超促排卵用于PCOS患者行IVF-ET的临床研究

目的:研究来曲唑(LE)在多囊卵巢综合征(PCOS)患者超促排卵行IVF-ET中的应用。方法:90例PCOS患者随机分成LE组(n=49)和GnRHa长方案组(对照组,n=41),比较组间的促排卵天数、促性腺激素(Gn)使用剂量、获卵数、受精率、卵裂率、优质胚胎率、种植率和临床妊娠率以及卵巢过度刺激综合征(OHSS)发生率。结果:LE组与对照组的Gn剂量分别为18.0±6.6支和29.3±9.5支,促排卵天数分别为7.8±1.3 d和10.0±1.2 d,获卵数分别为7.9±4.1个和19.8±7.2个,MⅡ卵率分别为74.5%和82.9%,启动周期中-重度OHSS发生率4.1%(2/49)vs 29.3%(12/41),差异均具有统计学意义(P<0.05),而组间的种植率和临床妊娠率(33.3%vs27.5%和51.1%vs 48.5%)差异无统计学意义(P>0.05)。结论:LE用于PCOS超促排卵行IVF-ET与传统的GnRHa长方案相比,在不影响临床妊娠率的前提下,可以有效减少促排卵时间和Gn使用剂量,降低OHSS发生风险,具有极大的临床应用前景。     

适当延后促排卯启动时间有利于IVF-ET结局

目的:探讨不同促排卵(COH)启动时间对IVF-ET结局的影响.方法:回顾性分析845个IVF-ET周期结局.分别比较过度抑制组(A组)及非过度抑制组(B组)中d 3-5启动(亚组1)和d 6-8启动(亚组2)的临床结局.同时比较GnRH-a降调后常规d3 COH启动病例(C组)中,出现垂体过度抑制与未出现过度抑制组的临床结局.结果:C组中垂体过度抑制者与非过度抑制者相比,Gn用量、Gn刺激天数增加,获卵数、优质胚胎数、胚胎种植率、持续妊娠率低(P＜0.05).hCG注射日E2、LH下降(P＜0.01).而A组与B组的比较中均得出同样的结论:d 6-8启动比d 3-5启动获得更多的直径＞14mm的卵泡数及获卵教,Gn用量及Gn使用天数减少,hCG注射日有更高的E2和LH水平(P均＜0.05),但是2种启动时间相比获得的优质胚胎数、胚胎种植率及持续妊娠率均无统计学差异(P均＞0.05).结论:延迟COH启动时间可减少卵巢刺激时间、Gn用量,可增加＞14 mm卵泡数及获卵数,且不影响优质胚胎数、胚胎种植率及持续妊娠率.     

不同促排卵方案在多囊卵巢综合征患者IVF-ET治疗中的应用分析

目的:探讨GnRH激动剂(GnRH-a)长方案(Ⅰ组,58周期)、GnRH-a短方案(Ⅱ组,52周期)、GnRH拮抗剂(GnRH-A)方案(Ⅲ组,41周期)3组对多囊卵巢综合征(PCOS)患者行体外受精-胚胎移植(IVF-ET)治疗的临床结局,寻求更适宜PCOS患者的促排卵治疗方案。方法:回顾性分析2008年1月~2010年6月行IVF-ET的PCOS患者151周期,根据所采取的不同促排卵方案分成3组,比较各组患者基本特征、Gn用药天数、Gn量、HCG日LH、P、E2水平、获卵数、受精率、优质胚胎率、妊娠率、周期取消率、OHSS发生率等。结果:3组患者基本特征差异无统计学意义(P>0.05);Gn用药天数和Gn量Ⅲ组均显著低于其他两组(P<0.05);3组HCG日LH、P、E2水平、获卵数、受精率、优质胚胎率、流产率的差异无统计学意义(P>0.05);Ⅲ组妊娠率最高(P<0.05);周期取消率Ⅲ、Ⅱ组与Ⅰ组相比显著降低(P<0.05),OHSS发生率Ⅲ组明显低于Ⅰ组与Ⅱ组(P<0.05)。结论:对于行IVF-ET的PCOS患者使用GnRH-A方案有效减少了Gn的用量和天数,提高了妊娠率,降低了周期取消率和OHSS发生率,减轻了患者的经济和心理负担,是PCOS患者行IVF-ET较为适宜的促排卵方案。     

适当延后促排卵启动时间有利于IVF-ET结局

目的:探讨不同促排卵(COH)启动时间对IVF-ET结局的影响。方法:回顾性分析845个IVF-ET周期结局。分别比较过度抑制组(A组)及非过度抑制组(B组)中d3-5启动(亚组1)和d6-8启动(亚组2)的临床结局。同时比较GnRH-a降调后常规d3COH启动病例(C组)中,出现垂体过度抑制与未出现过度抑制组的临床结局。结果:C组中垂体过度抑制者与非过度抑制者相比,Gn用量、Gn刺激天数增加,获卵数、优质胚胎数、胚胎种植率、持续妊娠率低(P<0.05)。hCG注射日E2、LH下降(P<0.01)。而A组与B组的比较中均得出同样的结论:d6-8启动比d3-5启动获得更多的直径>14mm的卵泡数及获卵数,Gn用量及Gn使用天数减少,hCG注射日有更高的E2和LH水平(P均<0.05),但是2种启动时间相比获得的优质胚胎数、胚胎种植率及持续妊娠率均无统计学差异(P均>0.05)。结论:延迟COH启动时间可减少卵巢刺激时间、Gn用量,可增加>14mm卵泡数及获卵数,且不影响优质胚胎数、胚胎种植率及持续妊娠率。     

长方案垂体降调节对体外受精-胚胎移植结果的影响

目的:探讨长方案达到垂体降调节的时间长短是否会对控制性超促排卵(COH)和体外受精-胚胎移植(IVF-ET)的结果产生影响。方法:回顾性分析568个用长方案进行控制性超促排卵的IVF-ET周期,根据达到垂体降调节标准的时间长短分组:A组,14d达到降调节标准,419个周期;B组,14d达到降调节标准,149个周期,比较组间的促排卵情况及IVF-ET结果。结果:Gn用量、Gn用药天数、获卵数、注射hCG日子宫内膜厚度组间均无统计学差异(P>0.05),移植胚胎数、可移植胚胎数、种植率组间也均无统计学差异(P>0.05)。妊娠率A组略高于B组,但无统计学差异。A组降调后E2明显低于B组(P<0.05),受精率明显高于B组(P<0.05)。结论:长方案达到垂体降调节所需时间长短不影响COH结果及临床妊娠率,但较早达到降调节者临床妊娠率有增高趋势。     

长效促性腺激素释放激素激动剂用于体外受精-胚胎移植中降调节后延迟卵巢启动时间的探讨

目的:探讨体外受精-胚胎移植(IVF-ET)中应用半量长效促性腺激素释放激素激动剂(GnRHa)降调节后,延迟超促排卵(COH)启动时间对实验室和临床结局等的影响。方法:将IVF中207个周期分为3组,使用不同剂型的GnRHa和COH的启动时间。结果:常规组的取消周期数最多(P<0.01)。COH启动日,延迟组和对照组之间E2、LH水平高于常规组(P均<0.01)。HCG注射日,对照组的E2水平最高;延迟组和对照组中LH水平高于常规组(P均<0.01),刺激天数和Gn用量少于常规组(P均<0.005);获卵数、受精率、可移植胚胎数、临床妊娠率、胚胎种植率和MⅡ期卵子高于常规组(P均<0.05)。结论:延迟COH启动时间可减少卵巢刺激时间、Gn用量,增加获卵数、成熟卵子数,可移植胚胎数和胚胎种植率,提高IVF的妊娠率。     

三种促排卵药物在体外受精/卵胞质内单精子注射-胚胎移植的临床疗效分析

目的:比较体外受精/卵胞质内单精子注射-胚胎移植(IVF/ICSI-ET)控制性超促排卵(COH)中3种不同促排卵药物的临床疗效。方法:回顾性分析行IVF/ICSI治疗的3种COH方案[短方案、长方案与克罗米芬(CC)+促性腺激素(Gn)方案]不孕症患者的3 347个移植周期的临床资料。3种COH方案内再各分为3个组,分别为高纯度尿促性素(HP-h MG)组、人尿促性素(h MG)组、重组卵泡刺激素(r FSH)组。比较3组患者给予Gn的时间、Gn用量、人绒毛膜促性腺激素(h CG)注射日雌二醇(E2)、孕酮(P)水平及子宫内膜厚度、获卵数、受精率、卵裂率、有效胚胎率、平均移植胚胎数、临床妊娠率和种植率。结果:h MG组无论在Gn使用的天数和剂量上,都显著高于HP-h MG组与r FSH组。在CC+Gn方案中,HP-h MG组在h CG注射日E2峰值最低。在长方案中,HP-h MG组h CG注射日的P水平最低(P0.05)。3种方案中各组的h CG注射日子宫内膜厚度、获卵数、受精率、卵裂率、有效胚胎率、平均移植胚胎数、临床妊娠率与种植率比较,均无统计学差异(P0.05)。结论:HP-h MG在h CG注射日具有较低P水平,使得内膜更利于胚胎着床,其COH临床效果上与其他促排卵药物一样有效、安全。     

减少GnRHa剂量对长方案促排卵卵巢反应性的影响

目的:探讨减少GnRHa剂量对长方案促排卵的卵巢反应性影响。方法:对37例采用长方案进行促排卵且第一周期未妊娠或流产的患者进行自身对照研究,第一个周期GnRHa用量为0.05mg/d,第二个周期GnRHa用量为0.03mg/d。结果:Gn使用天数、Gn用量、受精率第一、第二促排卵周期间无显著性差异(P>0.05)。获卵数、可移植胚胎数第二周期组较第一周期组显著增加(P<0.05)。结论:本研究认为在长方案促排卵过程中减少GnRHa的剂量可以增加获卵数,改善卵巢反应性,增加IVF妊娠率。     

A preliminary study on reduced dose (33 or 25 microg) gonadotropin-releasing hormone agonist long protocol for multifollicular ovarian stimulation in patients with high basal serum follicle-stimulating hormone levels undergoing in vitro fertilization-embryo transfer.

The aim of the present study was to evaluate the clinical efficacy of half-dose (50 mug) and further reduced dose (33 or 25 mug) gonadotropin-releasing hormone agonist (GnRH-a; triptorelin) long protocols for multifollicular ovarian stimulation (MFOS) for patients with high basal serum follicle-stimulating hormone (FSH) level undergoing in vitro fertilization and embryo transfer (IVF-ET). One hundred and two IVF-ET cycles performed in 84 infertile patients with high basal serum FSH (>10.0 mIU/ml) were included in this retrospective study. Study subjects were assigned to two groups: continuous half-dose GnRH-a long protocol (group A, n = 63) vs. further reduced dose GnRH-a long protocol (group B, n = 39) from half-dose at the start of GnRH-a to one-third or one-quarter dose after pituitary downregulation. Exogenous FSH or human menopausal gonadotropin was administered for MFOS in step-down mode, four or fewer embryos were transferred, and the outcomes of MFOS were compared between the two groups. Serum estradiol (E(2)) level on the day of human chorionic gonadotropin administration was significantly higher in group B (mean +/- standard deviation (SD): 1318.3 +/- 1120.4 vs. 2054.9 +/- 1773.5 pg/ml, p = 0.015). The number of transferable and good-quality embryos was also significantly higher in group B (mean +/- SD: 2.9 +/- 1.7 vs. 3.7 +/- 2.0, p = 0.027; 1.8 +/- 1.4 vs. 2.7 +/- 2.0, p = 0.020). No statistically significant difference in the outcomes was observed with respect to the dose of gonadotropins administered, the number of oocytes retrieved or the clinical pregnancy rate. In conclusion, GnRH-a long protocol with a reduced dose, tapered from the starting half-dose to a third or a quarter of the normal dose after pituitary suppression, may be beneficial for MFOS in IVF-ET patients with a high basal serum FSH level. A further prospective randomized controlled study on a larger scale is needed to confirm these findings.     

Effect of salpingectomy on ovarian response to superovulation in an in vitro fertilization–embryo transfer program

Objective: To investigate the effect of salpingectomy on the response of each ovary in patients undergoing an IVF-ET treatment cycle and to compare the results with those of patients who had not had surgery and were undergoing IVF-ET during the same period.

Design: A prospective study.

Setting: Tertiary referral academic IVF unit.

Patient(s): Twenty-nine ET cycles were evaluated in 29 patients who previously had undergone unilateral salpingectomy because of ectopic pregnancy (study group). Seventy-three patients with unexplained or male factor infertility served as controls.

Intervention(s): Ovulation induction and IVF-ET.

Main Outcome Measure(s): In the study group, mean ovarian volume, number of follicles, and number of oocytes recovered from each ovary were assessed and compared. The overall results, cycle characteristics, and pregnancy rates of the two groups were compared.

Result(s): Among the patients who had undergone salpingectomy, significantly fewer follicles developed and consequently fewer oocytes were retrieved from the ovary on the operated side (4.4 versus 8.2 follicles and 3.8 versus 6.0 oocytes). There were no differences in the total numbers of follicles and oocytes recovered from both ovaries, the cycle characteristics, or the pregnancy rates between study and control groups.

Conclusion(s): Salpingectomy has no detrimental effect on the total ovarian performance during IVF-ET treatment or on the outcome of IVF-ET. However, the ipsilateral ovary could be adversely affected. This could be detrimental in selected patients undergoing IVF-ET, in whom the second ovary already is compromised or missing.     

不同预处理促性腺激素拮抗剂方案在超促排卵中应用的临床分析

目的:探讨如何在体外受精-胚胎移植(IVF-ET)周期中更有效地运用拮抗剂方案。方法:回顾性分析319个使用拮抗剂方案进行IVF-ET无输卵管积液、无内膜息肉及无子宫解剖结构异常的新鲜移植周期。根据拮抗剂治疗前使用短效激动剂(n=125,A组)、口服避孕药(达英-35)(n=113,B组)和未处理组(n=81,C组)分组,比较各组患者的年龄、促性腺激素(Gn)使用天数和剂量、注射hCG日LH和E2水平、获卵数、优质胚胎率、临床妊娠率等。同时以261个促性腺激素激动剂长方案移植周期为对照组(D组)作进一步对比。结果:C组年龄(32.9±4.8岁)较其它组年龄明显偏大,P<0.05;A和B组Gn使用剂量大于C组,其中A组明显增多(P<0.01);A和B组hCG注射日LH水平均较C组明显低,其中A组LH值最低(P<0.01);A组获卵数最多(P<0.05);B组子宫内膜最薄(P<0.01)。3组的受精率、优质胚胎率均无统计学差异(P>0.05)。A组、B组和C组临床妊娠率分别为:32.8%、17.7%和37.0%,B组临床妊娠率显著低于A、C组(P<0.01)。C组、D组间临床妊娠率比较无统计学差异(37.0%vs 40.2%,P>0.05);C组Gn使用的时间和剂量均比D组明显减少(P<0.05)。结论:在IVF-ET中GnRH拮抗剂治疗前使用达必佳预处理未能提高妊娠率,使用过达因-35避孕的患者妊娠率明显下降,而未使用任何药物的患者接受GnRH拮抗剂超促排卵方案,能获得比较好的临床结局。     

IVF-ET中卵巢低反应患者拮抗剂方案中应用生长激素的研究

目的:研究卵巢低反应(POR)患者采用拮抗剂方案加用生长激素(GH)对子宫内膜容受性及妊娠结局的影响。方法:对采用拮抗剂方案促排卵行体外受精-胚胎移植(IVF-ET)助孕的188例POR患者的资料进行回顾性分析。以加用GH者为研究组(n=98),其余不加用GH者为对照组(n=90),比较组间的临床资料、实验室数据及妊娠结局,以评估GH治疗对POR患者的临床疗效。结果:研究组的Gn使用时间、Gn RH-A使用时间及总Gn使用量显著少于对照组,而获卵数、MII卵子数、受精卵数、优质胚胎数、h CG注射日血E2水平均显著高于对照组,差异均有统计学意义(P0.05);h CG注射日子宫内膜厚度组间比较差异无统计学意义(P0.05),但研究组子宫内膜血流改善显著,差异有统计学意义(P0.05);研究组生化妊娠率、临床妊娠率、种植率、活产率略高于对照组,但差异无统计学意义(P0.05)。结论:对于POR患者,GH改善了子宫内膜血流,可能提高了子宫内膜容受性,但对妊娠结局没有改善。     

Comparison of a single half-dose, long-acting form of gonadotropin-releasing hormone analog (GnRH-a) and a short-acting form of GnRH-a for pituitary suppression in a controlled ovarian hyperstimulation program

OBJECTIVE: To compare the effect of a single low-dose leuprolide acetate depot (LA depot) and leuprolide acetate (LA) on pituitary down-regulation in women undergoing controlled ovarian hyperstimulation (COH). DESIGN: Retrospective study.Setting: An IVF unit of an academic medical center. PATIENT(s): Women who underwent COH and IVF-ET. INTERVENTION(s): Pituitary down-regulation with half-dose LA depot (1.88 mg sc, group 1) or LA (0.5 mg/d sc, group 2) was started on menstrual days 21-23. MAIN OUTCOME MEASURE(s): The concentrations of estradiol (E(2)), FSH, LH, gonadotropin dosages, the numbers of oocytes retrieved, oocytes fertilized and embryos transferred, and pregnancy rates of the two groups were compared. RESULT(s): A total of 289 patients in group 1 and 158 in group 2 were included. There were no statistically significant differences between the two groups in baseline concentrations of E(2) and FSH, concentrations of E(2), FSH, and LH during hCG administration, gonadotropin dosage, the number of oocytes retrieved, the number of oocytes fertilized and embryos transferred, and pregnancy rates. CONCLUSION(s): Single half-dose LA depot offers a useful alternative for pituitary suppression in ovarian stimulation for IVF.     

Effect of prolonged gonadotropin-releasing hormone agonist therapy on the outcome of in vitro fertilization-embryo transfer in patients with endometriosis

OBJECTIVE: To evaluate the effect of a 3-month course of GnRH agonist administered immediately before IVF-ET in infertile patients with endometriosis. DESIGN: Prospective, randomized trial. SETTING: Three tertiary care assisted reproductive technology programs. PATIENT(S): IVF-ET candidates with surgically confirmed endometriosis. INTERVENTION(S): Twenty-five patients received three courses of a long-acting GnRH agonist, 3.75 mg i.m. every 28 days, followed by standard controlled ovarian hyperstimulation. Twenty-six patients received standard controlled ovarian hyperstimulation with mid-luteal phase GnRH agonist down-regulation or microdose flare regimens. MAIN OUTCOME MEASURE(S): Response to controlled ovarian hyperstimulation, ongoing pregnancy rates per cycle, group implantation rates, and implantation rate per embryo transfer procedure. RESULT(S): The extent of surgically confirmed endometriosis was greater in patients who received the long-acting GnRH regimen for 3 months before IVF-ET. The groups did not differ significantly in terms of dose or duration of gonadotropin stimulation, number of oocytes retrieved, fertilization rate, or number of embryos transferred. Patients who received the long-acting GnRH regimen had significantly higher ongoing pregnancy rates (80% vs. 53.85%) and a trend toward higher implantation rates (42.68% vs. 30.38%). CONCLUSION(S): Prolonged use of GnRH agonist before IVF-ET in patients with endometriosis resulted in significantly higher ongoing pregnancy rates than did standard controlled ovarian hyperstimulation regimens. No deleterious effect on ovarian response was observed.     

子宫内膜异位症患者IVF促排卵不同降调节方案的比较

目的:探讨子宫内膜异位症(EMs)患者合适的降调节方案。方法:收集因中-重度EMs接受IVF-ET治疗的139例不孕患者的资料,按不同的降调节方案分为超长方案(A组)、GnRHa长方案(B组)、GnRHa短方案(C组)3组,回顾性比较分析3组患者的治疗结局。结果:A组的促性腺激素(gonadotropic hormone,Gn)用量(尤其是hMG)显著多于B组和C组,差异有统计学意义(P<0.05);而冷冻周期率、临床妊娠率与种植率显著高于C组(P<0.05),与B组比较有上升趋势,但差异无统计学意义(P>0.05)。结论:EMs患者接受IVF/ICSI-ET治疗时,建议采用超长方案和常规长方案诱导排卵,以提高患者的临床妊娠率。     

多囊卵巢综合征患者IVF治疗中超促排卵方案的对比研究

目的:探讨不同的超排卵方案对多囊卵巢综合征(PCOS)患者实施IVF-ET治疗过程的影响。方法:回顾分析行IVF治疗、长方案超促排卵的PCOS患者134个移植周期,比较分析不同超促排卵方案、促排卵药物的IVF-ET结局。结果:①递增方案组(n=7,6)总Gn使用量明显大于递减方案组(n=74)、Coasting方案组(n=16)和恒量方案组(n=18)(P<0.05)。②后期添加hMG组(n=61)总Gn使用量明显大于单用FSH组(n=73)(P<0.05),着床率也明显降低(P<0.05),但临床妊娠率无显著性差异(P=0.064);③普丽康组(n=43)与果纳芬+hMG组(n=22)及普丽康+hMG组(n=39)相比,总Gn使用量明显减少(P<0.05),而与果纳芬组(n=30)间无统计学差异;普丽康组与普丽康+hMG组相比,获卵数明显增加(P<0.05)。结论:PCOS患者的长方案超排卵方案中,递增方案增加了Gn使用总量而临床妊娠率有偏低的趋势;添加hMG不能提高着床率和临床妊娠率;单纯普丽康超排卵有减少总Gn使用量,增加获卵数的趋势。     

Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin)

OBJECTIVE: To confirm the value of a single dose of 3 mg of cetrorelix in preventing the occurrence of premature LH surges. DESIGN: Multicenter randomized, prospective study. SETTING: Reproductive medicine units. PATIENT(S): Infertile patients undergoing ovarian stimulation for IVF-ET. INTERVENTION(S): A single dose of 3 mg of cetrorelix (Cetrotide; ASTA Medica, Frankfurt, Germany) (115 patients) was administered in the late follicular phase. A depot preparation of triptorelin (Decapeptyl; Ipsen-Biotech, Paris, France) was chosen as a control agent (39 patients). Ovarian stimulation was conducted with hMG (Menogon; Ferring, Kiel, Germany). MAIN OUTCOME MEASURE(S): Premature LH surges (LH level >10 IU/L), progesterone level greater than 1 ng/L, and IVF results. RESULT(S): No LH surge occurred after cetrorelix administration. The patients in the cetrorelix group had a lower number of oocytes and embryos. The percentage of mature oocytes and fertilization rates were similar in both groups, and the pregnancy rates were not statistically different. The length of stimulation, number of hMG ampules administered, and occurrence of the ovarian hyperstimulation syndrome were lower in the cetrorelix group. Tolerance of cetrorelix was excellent. CONCLUSION(S): A cetrorelix single-dose protocol prevented LH surges in all patients studied. It compares favorably to the "long protocol" and could be a protocol of choice in IVF-ET.